**Table 1: Baseline characteristics**

|  |  |  |
| --- | --- | --- |
| **Baseline variable** | **Europe** | **India** |
|  | 12mg (n=315) | 6mg (n=298) | 12mg (n=182) | 6mg (n=187) |
| **Country of Inclusion** |  |  |  |  |
| * Denmark
 | 251 (79.7%) | 234 (78.5%) | - | - |
| * Sweden
 | 40 (12.7%) | 39 (13.1%) | - | - |
| * Switzerland
 | 24 (7.6%) | 25 (8.4%) | - | - |
| * India
 | - | - | 182 (100%) | 187 (100%) |
| Age in years - median (IQR) | 65.0(57.0-74.5) | 66.0(57.0-73.8) | 63.5(54.0-70.0) | 61.0 (51.5-70.0) |
| Sex (n and %)* Male
 | 214 (67.9%) | 214 (71.8%) | 132 (72.5%) | 117 (62.6%) |
| Weight in kgs - median (IQR) | 90.0 (76.0-104.5) | 90.0 (77.0-100.0) | 65.5(60.0-73.8) | 68.0(60.0-75.0) |
| **Coexisting conditions (n and %)** |  |  |  |  |
| * Ischemic heart disease or heart failure
 | 46 (14.6%) | 47 (15.8%) | 21 (11.5%) | 22 (11.8%) |
| * Diabetes mellitus
 | 62 (19.7%) | 87 (29.2%) | 73 (40.1%) | 76 (40.6%) |
| * Chronic obstructive pulmonary disease
 | 49 (15.6%) | 46 (15.4%) | 8 (4.4%) | 10 (5.3%) |
| * Immunosuppressive therapy within 3 months prior to randomization
 | 27 (8.6%) | 24 (8.1%) | 13 (7.1%) | 19 (10.2%) |
| * Chronic use of systemic glucocorticoids
 | 11 (3.5%) | 15 (5.0%) | 2 (1.1%) | 1 (0.5%) |
| Limitations in the use of CPR or life support at randomization (n and %) | 29 (9.2%) | 25 (8.4%) | 1 (0.5%) | 1 (0.5%) |
| Time from onset of symptoms to hospitalization in days - median (IQR)\* | 8.0(5.0-10.0) | 8.0(5.0-10.0) | 5.0(3.0-7.0) | 5.0(3.0-7.0) |
| Time from hospitalization to randomization in days- median (IQR) | 2.0(1.0-3.0) | 1.0(1.0-3.0) | 2.0(1.0-3.0) | 2.0(1.0-3.0) |
| **Place of enrollment, n and %** |  |  |  |  |
| * Intensive care unit
 | 222 (70.5%) | 215 (72.1%) | 167 (91.8%) | 178 (95.2%) |
| * Hospital ward
 | 61 (19.4%) | 53 (17.8%) | 5 (2.7%) | 1 (0.5%) |
| * Emergency department
 | 14 (4.4%) | 13 (4.4%) | 8 (4.4%) | 8 (4.3%) |
| * Intermediate care unit
 | 18 (5.7%) | 17 (5.7%) | 2 (1.1%) | 0 (0.0%) |
| **Type of oxygen supplementation** |  |  |  |  |
| **Nasal cannula or open mask, n and %** | 190 (60.3%) | 176 (59.1%) | 82 (45.1%) | 82 (43.9%) |
| *Flow rate in L/min, median (IQR)* | 23.5(15.0-37.0) | 25.0(15.0-40.0) | 15.0(12.0-45.0) | 16.0(12.0-48.8) |
| **Noninvasive ventilation or continuous positive airway pressure, n and %** | 39 (12.4%) | 45 (15.1%) | 79 (43.4%) | 83 (44.4%) |
| *Fio2 in %, median (IQR)#* | 80.0(67.5-99.0) | 70.0(64.0-100.0) | 50.0 (50.0-60.0) | 50.0(40.0-60.0) |
| *Duration before randomization in days, median (IQR)* | 1.0 (0.0-1.0) | 1.0 (0.0-1.0) | 1.0 (0.0-1.0) | 1.0 (0.0-1.5) |
| **Invasive ventilation, n and %** | 86 (27.3%) | 77 (25.8%) | 21 (11.5%) | 22 (11.8%) |
| *Fio2 in %, median (IQR)$* | 55.0 (45.0-70.0) | 60.0(45.0-90.0) | 70.0(60.0-90.0) | 62.5(50.0-70.0) |
| *Duration before randomization in days, median (IQR)* | 1.0 (0.0-1.0) | 1.0 (0.0-1.0) | 1.0 (0.0-1.0) | 1.0 (1.0-1.0) |
| **Baseline Oxygenation status** |  |  |  |  |
| *PaO2 in mmHg (median/IQR)^* | 69.8(61.5-83.1) | 70.0(62.2-81.0) | 76.5(60.8-100.0) | 72.0(58.8-83.4) |
| *Saturation in % (median/IQR)&* | 94.0(91.0-96.0) | 93.0(91.0-96.0) | 95.0(91.0-97.0) | 94.0(90.0-96.5) |
| Lactate concentration in mg/dl (median/IQR)@ | 15.3(11.7-23.4) | 15.8(11.7-21.6) | 10.8(6.3-18.0) | 13.5(8.1-18.2) |
| Vasopressors or inotropes | 68 (21.6%) | 57 (19.1%) | 13 (7.1%) | 11 (5.9%) |
| Kidney replacement therapy | 7 (2.2%) | 7 (2.3%) | 4 (2.2%) | 7 (3.7%) |
| **Anti-inflammatory agents** | 31 (9.8%) | 31 (10.4%) | 27 (14.8%) | 26 (13.9%) |
| *IL-6 receptor antagonists* | 25(7.9%) | 23 (7.7%) | 27 (14.8%) | 24 (12.8%) |
| *Janus kinase inhibitor* | 0 (0.0%) | 0 (0.0%) | 8 (4.4%) | 7 (3.7%) |
| *Other* | 7 (2.2%) | 8 (2.7%) | 2 (1.1%) | 2 (1.1%) |
| **Antiviral agents** | 162(51.4%) | 157(52.7%) | 150(82.4%) | 161(86.1%) |
| *Remdesivir* | 157(49.8%) | 151 (50.7%) | 150 (82.4%) | 159 (85.0%) |
| *Convalescent plasma* | 4(1.3%) | 7(2.3%) | 7(3.8%) | 10(5.3%) |
| *Other* | 9(2.9%) | 4(1.3%) | 0(0.0%) | 2(1.1%) |

\* proportion missing 5.1%; # missing 1.2% ; $ missing 0.1%; ^missing 5.2%; & missing 1.4%; @missing 10.8%

Add all abbreviations

**Table 2: Outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcome** | **Europe** | **Effect estimates with 99% CI\*** | **India** | **Effect estimates with 99% CI** | **P value for test of interaction** |
|  | 12mg(n=315) | 6mg(n=298) |  | 12mg(n=182) | 6mg(n=187) |  |  |
|  |  |  |  |  |  |  |  |
| Mortality at day 28-n (%) | 57 (18.3%) | 76(25.8%) | -8.3(-17.7 to 1) | 76(42.2%) | 79(42.7%) | 0.1(-10.0 to 10.0) | 0.12 |
| Serious adverse reactions at day 28 - n (%) | 40 (12.7%) | 41(13.8%) | -1.0(-7.1 to 5.2) | 16(8.8%) | 24(12.8%) | -5.3(-16.2 to 5) | 0.33 |
| Mortality at day 90 - n (%) | 77(24.8%) | 94(32.1%) | -7.4(-17.1 to 2.0) | 80(44.4%) | 86(46.5%) | -1.4(-12.8 to 9.8) | 0.30 |
| No. of days alive without life support at day 90- median (IQR) | 83.0(35.5-90.0) | 80.0(8.0-90.0) | 6.1(-1.3 to 13.4) | 89.5(5.0-90.0) | 74.5(5.0-90.0) | 1.7(-8.4 to 11.8) | 0.37 |
| No. of days alive and out of hospital at day 90- median (IQR) | 63.0(0.0-77.8) | 54.0(0.0-76.0) | 4.4(-2.3 to 11.0) | 50.5(0.0-78.0) | 0.0(0.0-78.0) | 3.7(-5.4 to 12.8) | 0.88 |
| Mortality at day 180- n (%) | 82(26.8%) | 97(33.2%) | -6.7(-16.4 to 2.9) | 82(45.6%) | 87(47.0%) | -1.0(-12.3 to 10.3) | 0.30 |
| EQ-5D-5L index values- median (IQR)$ | 0.80(0.00-0.92) | 0.67(0.00-0.91) | 0.08(-0.01 to 0.16) | 0.85(0.00-1.00) | 0.74(0.00-1.00) | 0.02(-0.10 to 0.14) | 0.31 |
| EQ VAS – median (IQR)$ | 60.0(0.0-80.0) | 55.0(0.0-80.0) | 4.4(-3.1 to 11.9) | 80.0(0.0-100.0) | 65.0(0.0-95.0) | 2.6(-9.0 to 14.2) | 0.74 |

**\*For continuous outcomes, adjusted mean differences (in days) and for binary outcomes, adjusted risk differences (in percentage points) are presented. Adjustment is for stratification variables.**

**$These analyses are based on imputed datasets for missing values. All others are complete case analyses.**